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Chronic obstructive pulmonary disease (COPD) is characterized by the destruction of 
alveolar tissue (in emphysema) and airway remodeling (leading to chronic bronchitis) 
which cause difficulties in breathing. It is a public health concern with few therapeutic 
options that can reverse disease progression or mortality. This is in part because current 
treatments mainly focus on ameliorating symptoms induced by inflammatory pathways 
as opposed to curing disease. Hence, emerging research focused on upstream 
pathways are likely to be beneficial in the development of efficient therapeutics to 
address the root causes of disease. Because of the complexity of COPD and unknown 
targets for disease onset, simpler model organisms have proven to be useful tools in 
identifying disease-relevant pathways and targets. Here, we share results from a study 
that utilized a high-copy cDNA library genetic selection approach in Dictyostelium 
discoideum to identify protectors against cigarette smoke. Adenine nucleotide 
translocase was found to be protective against cigarette smoke in both Dictyostelium 
and human bronchial epithelial cells. We highlight that ANT defends against cigarette 
smoke by modulating metabolic activity and airway function. Interestingly, this work 
facilitates the interplay between metabolism and cytoskeletal function. We also share an 
exploration of the feedback between ANT and key players in cell mechanics. Overall, 
ANT being a modulator of metabolism, airway integrity, and cell shape change in the 
context of COPD makes it a potential therapeutic target to treat the disease.  
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Chapter 1: Introduction 
Chronic obstructive pulmonary disease (COPD), an illness that diminishes lung 
function to make breathing difficult, is one of the leading causes of death in the United 
States and worldwide (Lopez-Campos et al., 2016; Xu et al., 2020). An estimated 328 
million people have COPD worldwide as of 2010, and COPD is predicted to be the third 
leading cause of death in the world by 2030 (Lopez-Campos et al., 2016). Considering 
its impact on public health, research on what underlies COPD for the development of 
therapeutics has been underway for decades. Nonetheless, COPD continues to have a 
lack of therapeutic options that can reverse lung damage and prevent disease 
progression. Although research on COPD is ongoing and new therapeutics are currently 
in the pipeline, there continues to be few advances on the root causes of the disease 
and potential treatments to stop them. Here, I will include a general overview of COPD 
pathology and some of the therapeutic strategies currently in use. In addition, I will 
discuss emerging COPD research that has the potential to provide new breakthroughs 
for therapeutic development. 
 
General pathology and treatment of stable COPD 
A major cause of COPD is exposure to tobacco smoke. Continual exposure to 
the compounds in tobacco smoke induces tissue damage and inflammatory responses 
that lead to the primary phenotypes of the disease: emphysema and chronic bronchitis. 
Emphysema is characterized as the destruction of alveolar tissue. As a result, lung 
elasticity is lost by the degradation of the extracellular matrix (ECM) and alveolar cells 
are lost through apoptosis and autophagy (Tuder and Petrache, 2012). Apoptosis, 
inflammation, and ECM breakdown continue to propagate in self-amplifying loops that 
further the progression of emphysema (Tuder and Petrache, 2012). In the airways, 
inflammation can occur in both the large and small airways after exposure to tobacco 
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smoke. Chronic smoking also increases the chances of remodeling of the airways 
(Tuder and Petrache, 2012). Airway remodeling, the overproduction of mucus by airway 
goblet cells, and the increased difficulty in airway clearance contribute to airflow 
obstruction found in chronic bronchitis (Kim and Criner, 2013). One of the detriments of 
COPD is that the disease progresses even after smoking cessation (Tuder and 
Petrache, 2012). 
The 2020 Global Initiative for Chronic Obstructive Lung Disease offers 
recommendations for pharmacological COPD treatment based on patient symptoms and 
history of hospitalizations. Patients with mild COPD are generally given short-acting or 
long-acting β2-agonists and/or anti-muscarinic drugs (Global Initiative for Chronic 
Obstructive Lung Disease, 2020). β2-agonists stimulate β2-adrenergic receptors, leading 
to increased cAMP levels and protein kinase A activation (Global Initiative for Chronic 
Obstructive Lung Disease, 2020). Anti-muscarinic drugs block acetylcholine from binding 
to muscarinic receptors in the smooth muscle of the airways (Global Initiative for Chronic 
Obstructive Lung Disease, 2020). Through these mechanisms, both types of drugs 
reduce bronchoconstriction in airway smooth muscle. If symptoms worsen, inhaled 
corticosteroids can be used in combination with long-acting β2-agonists or anti-
muscarinic drugs that treat dyspnea and exacerbations (Global Initiative for Chronic 
Obstructive Lung Disease, 2020). Other options available for more severe cases of 
COPD include the PDE4 inhibitor, roflumilast, in combination with the drugs stated 
previously (Calverley et al., 2009). Current treatments for COPD mainly focus on 
addressing the symptoms of the disease, and evidence also suggests that some patients 
are resistant to inhaled corticosteroid treatment (Calverley et al., 2009). With the 
limitations of current treatments, more effective treatment strategies are needed. One 
potential strategy includes implementing a precision medicine approach that identifies 
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more upstream cellular and molecular pathways undermining the disease (Sidhaye et 
al., 2018).   
 
Recent COPD pipeline strategies 
In lieu of developing more disease-specific treatments, we describe some current 
efforts by other groups in the COPD pipeline to address disease onset (Figure 1.1). 
These efforts are heavily focused on targeting inflammatory pathways, which is relevant 
considering that inflammation is one of the main contributors to disease pathology. 
Nonetheless, inflammation in COPD is complex and involves a host of pathways 
(Barnes, 2016a). Therefore, targeting only one pathway may not necessarily be effective 
in treating COPD. In fact, several drug development strategies have failed to show 
efficacy possibly due to this issue. Delivery strategies may also contribute to this lack of 
efficacy. Oral drugs can cause off-target effects as they do not directly encounter the 
airways as efficiently as inhaled medications. Nevertheless, the following describes 




Oxidative stress is thought to be a significant driver of COPD as several disease-
related pathways are affected, including inflammation, aging, and DNA damage (Barnes, 
2020). While oxidative stress impacts many pathways, one that is well-studied involves 
Nrf2, a transcription factor, and its interaction with the negative regulator, Kelch-like 
ECH-associated protein 1 (KEAP1). Oxidative stress inactivates KEAP1, allowing Nrf2 to 
translocate into the nucleus where it activates pathways that increase antioxidant 
metabolism and attenuate inflammatory responses (Cuadrado et al., 2019). In the 
context of COPD, Nrf2 activity increases with cigarette smoke (CS) exposure due to the 
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increase in oxidative stress, but its activity declines with the progression of COPD 
(Sidhaye et al., 2019). In a study with a small group of COPD patients, gene expression 
levels downstream of Nrf2 were higher in bronchial epithelial cells of current smokers 
versus former smokers, consistent with Nrf2-related anti-inflammatory activity occurring 
 
with CS exposure (Sidhaye et al., 2019). CS extract (CS bubbled into cell media) also 
affects Nrf2 activity in differentiated primary normal human bronchial epithelial cells 
(NHBE) grown at air-liquid interface. Several oxidative stress responsive genes related 
to the Nrf2 pathways are upregulated with CS extract exposure (Sekine et al., 2019). In 
addition, Nrf2 protein expression has a biphasic relationship with CS extract exposure, 
increasing then decreasing with increased concentrations of CS extract (Sekine et al., 
2019). This result supports the idea that Nrf2 is important in regulating inflammatory 
responses from CS initially, but loses this ability with continual exposure to CS. 
 
Figure 1.1. The COPD pipeline focuses on targeting inducers of inflammation. 
Cigarette smoke activates numerous downstream pathways and targets that lead to 
inflammation including inflammatory mediators, oxidative stress, kinases, and 
phosphodiesterases. Current therapeutic strategies aim to reduce inflammatory 




Many lines of evidence implicate Nrf2 in COPD pathology; thus, Nrf2 and its 
associated signaling pathways are being pursued as therapeutic targets. One study 
identified the Receptor for Advanced Glycation End Products (RAGE), a member of the 
immunoglobulin superfamily, as a deactivator of Nrf2 activity in response to CS exposure 
(Lee et al., 2018). An antagonist for RAGE, FPS-ZM1, promoted Nrf2 translocation into 
the nucleus, allowing for decreased expression of damage-associated-molecular-
patterns signaling (Lee et al., 2018). Other agents that change Nrf2 expression and 
activity in airway cells include aspirin-triggered resolvin D1, crocin, sulforaphane, and 
schisandrin B (Dianat et al., 2018; Jia et al., 2017; Jiao et al., 2017; Posso et al., 2018). 
Sulforaphane, a natural compound found in cruciferous vegetables that activates Nrf2 by 
binding to KEAP1, proceeded into clinical trials for a variety of diseases (Cuadrado et al., 
2019). Nonetheless, in a trial for COPD, sulfurophane failed to show efficacy because 
Nrf2 gene expression and inflammatory markers levels did not consistently change after 
treatment in both alveolar macrophages and bronchial epithelial cells (Cuadrado et al., 
2019). This result is possibly due to poor drug penetration to the lung (Barnes, 2020). 
Something else to note is that this trial measured these parameters after a few weeks of 
treatment instead of a longer period of time (Wise et al., 2016). Other COPD drugs in the 
pipeline are non-electrophilic non-covalent drugs that target the Nrf2-KEAP1 protein-
protein interaction rather than the proteins themselves (Cuadrado et al., 2019). Non-
electrophilic PPI inhibitors have different pharmacodynamics and off-target effects 
compared to electrophilic drugs like sulforaphane, thus offering another avenue for drug 
development on Nrf2 (Cuadrado et al., 2019).     
 
Kinase-mediated pathways 
Several types of kinases induce chronic inflammation when activated, making 
them another therapeutic target group for COPD (Barnes, 2016b). Indeed, drugs have 
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been, or currently are in development that target a variety of kinase groups, including 
MAPK, receptor-tyrosine kinases (RTK), phosphoinositide-3-kinases (PI3Ks), JAK, and 
NF-κB (Barnes, 2016b). However, none have been approved for clinical use possibly 
due to issues such as target specificity and loss of efficacy over time (Barnes, 2016b). 
For instance, one group that drew attention for clinical development was the p38 MAPK 
family. Inhibiting p38 reduces inflammation in cellular and animal models, but many 
failed to show promise in clinical trials (Barnes, 2016b). An example is the p38α 
compound AZD7624, which decreases cytokine release in human alveolar macrophages 
but did not decrease exacerbations in COPD patients (Patel et al., 2018). However, work 
on developing and studying more specific inhibitors are underway. One such p38 
inhibitor with evidence of efficacy is RV-568. Classified as a narrow-spectrum kinase 
inhibitor with high potency for the α and γ isoforms of p38, RV-568 demonstrated anti-
inflammatory activity in monocytes, macrophages, and epithelial cells by inhibiting 
cytokine (CXCL8 and IL-6) release (Charron et al., 2017). Animal models also showed 
promising results, and in a small 14-day clinical trial, lung function improved with drug 
treatment (Charron et al., 2017).  
 
Phosphodiesterase inhibitors 
Interest in phosphodiesterase 4 (PDE4) inhibitors arose with the discovery that 
increasing intracellular cAMP levels can have anti-inflammatory effects. PDE4 subtypes 
are found in various immune cells and cells affected by immune response (Sakkas et al., 
2017). When they are inhibited, cAMP signaling allows for the upregulation of cAMP-
response element (CRE)-containing genes and the inhibition of NF-κB, which decreases 
inflammatory responses (Sakkas et al., 2017). The consequences of decreased cAMP 
via PDE upregulation can occur in airway cells and lung tissue as well. In a study with 
precision lung slices from CS-exposed mice, intracellular cAMP levels are decreased 
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based on FRET sensor measurements (Zuo et al., 2018). Protein and mRNA levels are 
lower for two paralogs of PDE4 (PDE4B, PDE4D; two of the four PDE4 genes) in these 
animals as well (Zuo et al., 2018). In another study by authors in the same group, they 
discovered that among patients, smokers have increased protein expression of PDE4D 
in the airway epithelium (Zuo et al., 2020). These works highlight PDE4 as a candidate 
for drug development against CS-induced inflammation.   
As mentioned above, the PDE4 inhibitor roflumilast is used for more severe 
cases of COPD (Global Initiative for Chronic Obstructive Lung Disease, 2020). 
Nevertheless, its efficacy is limited due to it being an oral drug and causing adverse side 
effects. Hence, more potent analogs of roflumilast are being developed (Moussa et al., 
2018). Several inhaled formulations of PDE4 inhibitors are in the pipeline too, which may 
improve their efficacy compared to roflumilast (Phillips, 2020). One of these drugs, 
CHF6001 showed promise in clinical trials by decreasing the inflammatory biomarkers 
LTB4, CXCL8, MMP9, TNFα, and MIP-1β in sputum of patients already on triple therapy 
with inhaled β2-adrenergic agonists, anti-muscarinics, and inhaled corticosteroids (Singh 
et al., 2019). Similar results appeared in alveolar macrophages and lung tissue from 
COPD patients with CHF6001 reducing TNFα production (more potently than roflumilast) 
and activating CREB (Lea et al., 2019).  
Another drug in clinical trials is ensifentrine/RPL554, a dual PDE3/PDE4 inhibitor. 
In addition to having anti-inflammatory effects, ensifentrine invokes bronchodilator 
effects (Singh et al., 2018). Ensifentrine also improves the effects of other 
bronchodilators when they are used in combination (Singh et al., 2018). The forced 
expiratory volume (volume of air forcefully expelled) in one second, or FEV1, increases 
with ensifentrine together with salbutamol (β2-adrenergic agonist), or ipratropium (anti-
muscarinic), both short-acting bronchodilators, than each short-acting bronchodilator 
alone (Singh et al., 2018). Ensifentrine with tiotropium, a long-acting bronchodilator with 
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anti-muscarinic effects, demonstrated similar benefits in FEV1 (Singh et al., 2018). More 
clinical trials are planned for ensifentrine, and other PDE4 inhibitors continue to be in the 
pipeline as well (Singh et al., 2018).   
 
Inflammatory mediators 
Interleukins serve as inflammatory mediators, and variants such as IL-4, IL-13, 
IL-9, and IL-5, which promote type 2 immunity, have been implicated in COPD disease 
progression (Barnes, 2018). Interleukins are released from a variety of cell types from 
exposure to tobacco smoke or other inhaled irritants. Aside from immune cells, tobacco 
smoke can cause epithelial cells, endothelial cells, and fibroblasts to release these 
mediators (Barnes, 2016a). The mediators then increase the number of macrophages, 
neutrophils, eosinophils, lymphocytes, dendritic cells, and other immune cells that induce 
inflammatory responses (Barnes, 2016a). 
Targeting these interleukins is of interest for developing therapeutics because of 
their role in promoting inflammatory responses. In a recent study, the authors found that 
IL-4, in an elastase-induced emphysema mouse model, is released from basophils and 
promotes alveolar destruction by increasing metalloproteinase-12 expression (Shibata et 
al., 2018). Another study demonstrated that IL-9 inhibition in a COPD mouse model also 
abrogates structural damage from CS exposure (Zou et al., 2018). In terms of drug 
development, IL-5 and its receptor IL-5Rα, key players in eosinophil-related 
inflammation, are targets of blocking antibodies mepolizumab, reslizumab, and 
benralizumab (Barnes, 2018). These drugs are approved for asthma but failed to show 
improved efficacy in COPD clinical trials (Barnes, 2018). Nonetheless, these drugs have 
not yet been tested for efficacious effects in COPD patient subgroups with eosinophilia. 
Other approved drugs for asthma target IL-13 and IL-4, but these drugs have not been 
extensively tested for COPD treatment. Clinical trials are still open for such studies with 
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dupilumab, an IL-4 and IL-13 receptor monoclonal antibody, being a candidate (Barnes, 
2018). 
Despite the interest in developing compounds for eosinophilic inflammation, 
research is ongoing to elucidate the effects of other inflammatory mediators on disease 
progression. Higher concentrations of cytokines, such as TNFα, exist in sputum and 
exacerbations of COPD patients (Barnes, 2018). IL-17 appears to have a role in small 
airway fibrosis in COPD model mice, and metalloproteinases (MMPs), particularly MMP-
9, are also targets of interest due to their involvement in alveolar wall destruction 
(Barnes, 2016a; Yanagisawa et al., 2017). Chemokines are also generating interest with 
CXCL8 and its receptor CXCR2 being the major targets. Interestingly, microRNAs, which 
likewise regulate inflammation, are involved in COPD with miR-155 expression being 
increased in COPD patients compared to nonsmokers (De Smet et al., 2020). MiR-155 
knockout mice have lower levels of inflammatory markers and cells, and elastase-
induced emphysema is attenuated in these mice. No miRNA-based therapeutics for 
COPD exist yet, although they have utility in diseases like cancer (Hanna et al., 2019).  
 
Opportunities for new breakthroughs 
Many of the current drug development strategies for COPD focus on targeting 
pro-inflammatory pathways. While these strategies are helpful in treating inflammation, 
lung damage remains and continues to be irreversible. Hence, there is a need for 
research into areas that have the potential to address these issues such as how lung 
damage occurs further upstream of inflammation. Delving into these upstream pathways 
may offer more potential therapeutic targets that may address the root causes of disease 
(Figure 1.2). In addition, conducting research on lung repair and regeneration may 






Figure 1.2. Emerging COPD biology offers potentials for new breakthrough in 
therapeutic development. The airway epithelium is composed of ciliated cells (blue), 
secretory cells (orange), and basal cells (green) on top of a basement membrane (BM) 
and extracellular matrix (ECM). Its role is to act as a barrier to toxins that enter in the 
airway including cigarette smoke. Continual exposure to cigarette smoke in the 
epithelium, however, can contribute to COPD phenotypes. Pathways that are affected 
by cigarette smoke upstream of inflammatory responses are currently being 
researched and may be helpful in identifying new targets for drug development. These 
pathways include airway hydration, the structural integrity of the airway epithelium and 
its barrier function, mitochondrial dysfunction and mtROS production, extracellular 




Uncovering new methodologies to assist in conducting these new areas of 
research could also be of interest. For example, model organisms can help to identify 
new disease-relevant targets. These targets or other pathways implicated in COPD can 
be further studied in human cellular disease models, which are also being currently 
researched and developed. More comments on these points and information on ongoing 
research are briefly described below. 
 
Mitochondria  
Mitochondria are a major source of endogenous reactive oxygen species (ROS) 
when under stress, making them viable targets for therapeutic research. Studies have 
focused on how mitochondrial dysfunction arises in the context of COPD and CS 
exposure (Aghapour et al., 2020). Many of these findings suggest that mitochondrial 
morphology, metabolism, and other functions become abnormal in human and mouse 
airway epithelial cells from CS. More recent findings highlight the effects of CS on 
mitochondrial morphology and the impact of these morphological changes. In human 
airway smooth muscle cells, CS causes mitochondrial fragmentation by decreasing 
expression of mitochondrial fusion protein, Mfn2, and increasing expression of fission 
protein, Drp1 (Aravamudan et al., 2017). This fragmentation leads to loss of 
mitochondrial membrane potential and defects in oxidative phosphorylation 
(Aravamudan et al., 2017). Interestingly, CS induces proliferation and airway remodeling 
in these cells, suggesting that the promotion of mitochondrial fission drives cells towards 
glycolysis for energy (Aravamudan et al., 2017). Similarly, in primary human alveolar 
type II cells from smokers and patients with emphysema, mitochondrial membrane 
potential and mtDNA repair are disrupted, leading to higher mtDNA damage, along with 
decreased mitochondrial fission (Kosmider et al., 2019).  
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Other proteins of interest affected by CS that contribute to mitochondrial 
dysfunction in the airway epithelium include Miro1, Nix, and pp66Shc. The expression 
levels of Miro1, a GTPase that is involved in mitochondrial shape and trafficking, are 
reduced after exposure to CS extract. Decreases in Miro1 cause defects in mitophagy, 
an important process in removing damaged mitochondria (Sundar et al., 2019). In the  
same vein, increases in Nix levels by CS extract induce mitophagy. Nix is involved in 
mitochondrial clearance and is related to the pro-apoptotic BH3-only proteins. When it is 
silenced by siRNA, CS extract-induced defects in ATP levels and mitochondrial 
membrane potential are ameliorated (Zhang et al., 2019). Finally, pp66Shc is an adaptor 
protein that is translocated into the mitochondria and generates ROS when 
phosphorylated by protein kinase C (PKC) isozymes. In airway epithelial cells exposed 
to CS extract, pp66Shc expression increases, resulting in increased mitochondrial ROS 
production (Zhang et al., 2018). Interestingly, pp66Shc silencing attenuates this effect on 
ROS and improves other mitochondrial processes (Zhang et al., 2018). Considering how 
involved these proteins are in mitochondrial injury, they can be potential therapeutic 
targets against mitochondrial-induced ROS. The pathways and processes related to 
these proteins (mitophagy, oxidative phosphorylation, fusion/fission) may also be 
valuable to examine further to identify additional targets to reduce the impact of ROS.  
 
Structural integrity of airway epithelium  
The airway epithelium is the first line of defense against any particulates and 
bacteria that enter the airway, yet this epithelium must maintain a barrier that is 
selectively permeable. Toxins such as CS can interrupt this barrier function, leading to 
the release of inflammatory signals that contribute to the onset of disease (Aghapour et 
al., 2018). On a mechanistic level, one reason for the loss of monolayer integrity is the 
disruption of cellular junctions. Proteins that comprise tight junctions (such as ZO-1 and 
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occludins) or adherens junctions (like E-cadherin) are downregulated in airway cells 
exposed to CS, resulting in a loss in barrier function reflected by a decrease in 
transepithelial resistance (Aghapour et al., 2018). Investigations into therapeutic 
compounds that target junctional proteins are underway, but they are still limited 
(Aghapour et al., 2018).  
To further understand barrier function in a related context, studies on cell 
mechanics and the cytoskeletal elements that interact with these junctions are 
transpiring. The actin cytoskeleton, which is linked to apical tight junctions and regulates 
cell structure, is affected by continual CS exposure in NHBEs (Aghapour et al., 2018). 
Actin assembly increases with more CS exposure, and cortical tension, a measure of 
cell stiffness, also rises (Nishida et al., 2017). Increased actin polymer levels and cell 
stiffness may contribute to the tissue remodeling and barrier dysfunction seen in COPD 
(Nishida et al., 2017). Indeed, other studies are emerging on actin and actin-associated 
proteins as potential regulators of disease. A study identified other actin-related proteins 
affected by CS via mass spectrometry: coactosin-like protein (COTL1), microtubule-
associated protein RP/EB family member 1 (MARE1), and heat shock protein B1 
(HSPB1) (D'Anna et al., 2017). Another identified potential protein affected by CS is the 
family-with-sequence-similarity-member-13A (FAM13A), a modulator of RhoA activity 
and actin dynamics (Castaldi et al., 2019). Rac1, a regulator of actin assembly, is also 
implicated in epithelial-to-mesenchymal transition (EMT) (Jiang et al., 2017). EMT, the 
process of the airway epithelium becoming more mesenchymal, is also thought to occur 
in COPD (Aghapour et al., 2018). Many proteins feed into this process, and future 
studies may reveal several cytoskeletal proteins as key players of EMT during COPD. 
The extracellular matrix (ECM) is an additional structural component of the 
airway epithelium that likely contributes to COPD phenotypes. In epithelial and alveolar 
cells, the breakdown of the ECM by proteases such as MMP-9 is presumed to help 
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cause emphysema by inducing inflammatory responses and airway remodeling 
(Aghapour et al., 2018). Indeed, the concentrations of biomarkers indicating ECM 
degradation for components like elastin, collagen I, and collagen IV, are higher in COPD 
patients as compared to healthy patients (Bihlet et al., 2017). Interestingly, when NHBEs 
are grown on a scaffold containing ECM from COPD patients, expression for COPD-
related genes is altered in these cells as compared to those grown on scaffolds from 
healthy patients (Hedstrom et al., 2018). The various changes in gene expression point 
towards a COPD phenotype, suggesting that changes in the ECM can disrupt the 
integrity of the airway epithelium (Hedstrom et al., 2018). While previous studies have 
attempted to develop therapeutics against the proteases (MMPs, etc.) that degrade the 
ECM, they have been unsuccessful in procuring an effective drug. Other proteins, such 
as cytoskeletal proteins that regulate the ECM, may be valuable targets. For example, 
defects in non-muscle myosin II (NM II), a force-generating motor protein important in 
cell structure and shape change, altered ECM remodeling in a mouse model and 
induced an emphysema-like phenotype (Kim et al., 2018). With modulators against 
some isoforms of NM II already discovered like 4-hydroxyacetophenone (4-HAP), they 
may be interesting candidates to test in therapeutic studies (Surcel et al., 2015).  
 
Airway hydration 
In addition to being a barrier that prevents bacteria and particulates from entering 
the airway, the epithelium functions to trap these particulates and remove them from the 
airway altogether. Mucus produced by goblet cells is released on the surface of the 
airway forming a layer of apical liquid called the airway surface liquid (ASL), which 
includes a mucus layer and an aqueous periciliary layer.  Mucociliary clearance is 
propagated by motile cilia along the surface of the epithelium (Ghosh et al., 2015). CS 
appears to affect mucociliary clearance by shortening cilia length, slowing down ciliary 
15 
 
beating, increasing mucus secretion, and lowering ASL height (Ghosh et al., 2015). This 
reduction in mucus clearance causes mucus build-up, which can be one of the causes of 
airway obstruction and infection found in chronic bronchitis (Ghosh et al., 2015). Cystic 
fibrosis (CF) comparably occurs from reduced airway hydration and lack of mucus 
clearance, making therapeutic targets from CF potentially useful for COPD treatment. 
Interestingly, CFTR, an anion channel that secretes Cl- to maintain airway hydration, is 
affected by CS exposure in human bronchial epithelial cells with a recent study by 
Marklew et al. suggesting CS leads to its inactivation by internalization trafficking 
(Marklew et al., 2019). Overall, CFTR and other ion channels, like the epithelial sodium 
channel (ENaC), that are responsible for airway hydration may be helpful targets to 
pursue and studies on their therapeutic potential are ongoing (Ghosh et al., 2015; Moore 
et al., 2018). 
 
Pro-regenerative strategies 
The progression of COPD disrupts repair mechanisms, resulting in irreversible 
lung damage. This observation has generated an interest in regenerative strategies such 
as stem cell and tissue-engineering treatments to repair areas of the lung that are 
already damaged. One extensively studied method is the infusion of mesenchymal 
stromal cells (MSC) at sights of injury. Interestingly, MSCs demonstrated anti-
inflammatory effects and induced paired in in vitro and in vivo mouse models, but clinical 
trials with MSCs have yet to show efficacy (Sun et al., 2018). MSCs did not affect 
pulmonary function or quality of life in these trials (Sun et al., 2018). Nonetheless, 
making changes to MSC clinical trial design and conducting more studies to understand 
how MSCs work mechanistically may address the disparity between the preclinical and 
clinical trial data.  
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Another therapeutic approach is to target and activate endogenous regenerative 
mechanisms in the lung that are affected by COPD. Most studies on lung regeneration 
have been conducted in mouse models, and they have procured relevant pathways, 
including Wnt/β-catenin, Notch, Fibroblast Growth Factor (FGF), retinoic acid (RA), and 
Hedgehog signaling (Ng-Blichfeldt et al., 2019). Interestingly, Wnt and Notch signaling 
are both disrupted in airway epithelial cells of COPD patients (Ng-Blichfeldt et al., 2019). 
Gene expression for proteins related to RA transport and activity are altered in COPD 
lung tissue and fibroblasts as well (Ng-Blichfeldt et al., 2019). Pharmacological activation 
of these pathways has also led to promising results in in vivo models. For instance, 
activation of the Wnt/β-catenin signaling pathway with lithium chloride attenuated 
emphysemic phenotypes by improving lung function and decreasing airspace 
enlargement in a mouse model (Ng-Blichfeldt et al., 2019). In some rat and mouse 
emphysema models, activating RA receptors (RARs) with all-trans RA (ATRA) induced 
alveolar regeneration and improved lung function (Ng-Blichfeldt et al., 2019). ATRA 
actually proceeded into clinical trials but failed to improve lung function after treatment 
(Ng-Blichfeldt et al., 2019; Sun et al., 2018). Another trial with palovarotene, a selective 
agonist of RAR-γ, also failed to show significant efficacy by not improving lung function 
(Ng-Blichfeldt et al., 2019; Sun et al., 2018).  
Although these trials along with the MSC trials have not yet procured promising 
treatments, there is still potential for regenerative strategies to be used therapeutically. 
The regenerative signaling pathways already mentioned (and some not mentioned here) 
can be furthered studied. More research needs to be done to thoroughly characterize 
these pathways to identify more promising targets and better understand how they 





Using 3D human-based disease models for pharmacological studies  
Animal models are heavily utilized to study COPD induced by CS exposure 
including mice, guinea pigs, rats, and dogs (Ghorani et al., 2017). These models along 
with immortalized human lung cell lines have contributed greatly to COPD research, but 
there are caveats to using them. For example, the lung anatomy and some COPD 
disease phenotypes vary in mouse and rat models when compared to human 
(Zscheppang et al., 2018). Treatments that appear to be effective in rodents may not 
necessarily be effective in humans as a result. Hence, the use of human-based disease 
models can be used to more effectively understand the cellular mechanisms underlying 
COPD (including the mechanisms of relevant targets found through model organisms) 
and evaluate the efficacy of treatments.  A variety of these models exist to study the 
airway epithelium. Most models are composed of primary cells from donor lungs that are 
grown under submerged conditions or at air-liquid interface on Transwell inserts where 
they can differentiate into secretory and ciliated cells (Hiemstra et al., 2019; Zscheppang 
et al., 2018).  
Recently, more complex 3D cell culture models have been developed. Unlike 
previous models, they allow for more representative human disease modeling by 
mimicking the structure of the lung and exposing cells to physiological mechanical cues 
(Hiemstra et al., 2019; Zscheppang et al., 2018). These models include organoids, which 
are self-assembling structures that are generally derived from stem/progenitor cells and 
embedded into a 3D matrix. Organoids can be generated from mouse or human cells, 
and they can be formed by variety of cell types including alveolar cells, airway secretory 
cells, and airway basal cells (Barkauskas et al., 2017). Considering that they are derived 
from stem cells, organoids are useful in studying lung formation and repair and epithelial 
function. These mechanisms are dysfunctional in COPD, so in a disease context, 
organoids can aid in identifying and understanding targets that underlie these 
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mechanisms. In addition, organoids can be useful in identifying potential therapeutics. 
For example, screens have been developed to find compounds that regulate basal cell 
differentiation and affect the ratio of ciliated and secretory cells, which is disrupted in 
COPD (Barkauskas et al., 2017). While these screens can be done with ALI cultures, 
organoid screens are faster, and many more samples can be evaluated (Barkauskas et 
al., 2017). Overall, organoids have the potential to identify new treatments and identify 
new disease mechanisms.  
In a similar vein, precision cut lung slices (PCLS), is another 3D model that 
mimics the complexity of the lung. They are lung tissue slices that encompass more of 
the lung’s complexity by containing all the cell types and the ECM composition in a 
particular area (Alsafadi et al., 2020; Liu et al., 2019). In the context of COPD, PCLS 
have been used to study the effects of tobacco smoke exposure on different targets, 
including the previously mentioned study by Zuo et al. (Zuo et al., 2018). Studying PCLS 
from diseased patients also provides useful information on disease and therapeutic 
mechanisms. For example, Frizzled-4 (FZD4), a WNT receptor, was downregulated in 
COPD PCLS (Skronska-Wasek et al., 2017). Pharmacological activation of FZD4 with 
valproic acid induced Wnt/β-catenin signaling and elastogenic components like insulin-
like growth factor 1 (IGF1) in COPD PCLS, making it a potential therapeutic target 
(Skronska-Wasek et al., 2017). In addition, PCLS have also been helpful in elucidating 
mechanisms for current treatments. In a study by Koziol-White et al., the researchers 
demonstrated that the combined use of a glucocorticoid (budesonide) and a β2-agonist 
(formoterol) additively promoted bronchodilation as opposed to either drug alone in 
PCLS (Koziol-White et al., 2020). Other experiments in both human PCLS and airway 
smooth muscle cells revealed that budesonide increases cAMP production, which further 
promotes bronchodilation by adding to the cAMP already released via β2-agonist 
treatment (Koziol-White et al., 2020). Overall, these studies are just a few examples of 
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how PCLS can be used to study disease mechanisms and evaluate therapeutic 
responses, which will be beneficial for future therapeutic development.     
Another model with similar characteristics to organoids and PCLS is lung-on-a-
chip. Lung-on-a-chip is a microfluidic device composed of microchannels lined with 
human cells that are exposed to a continuous flow of nutrients and growth factors. Many 
different types of models have been developed by different groups based on diseases 
and research areas (Shrestha et al., 2020). Some lung-on-a-chip models for asthma and 
COPD were developed in a study by Benam et al. (Benam et al., 2016). They 
interestingly demonstrated that their model could be used as a tool to evaluate 
therapeutic responses (Benam et al., 2016). An experimental anti-inflammatory 
bromodomain-containing protein 4 (BRD4) inhibitor suppressed neutrophil adhesion to 
inflamed cells on the chip. Interestingly, when the same drug was tested on 2D 
Transwell cultures, the efficacy of the BRD4 inhibitor was reduced (Benam et al., 2016). 
This result suggests that the inhibitor depended on the existence of flow in the model, 
demonstrating that the microfluidic aspect of the model was also useful in evaluating the 
mechanism of action for this drug (Benam et al., 2016). The results from this study and 
others exhibit the potential for lung-on-a-chip as a tool for drug studies in the future 
(Shrestha et al., 2020). Like organoids and PCLS, lung-on-a-chip simulates lung tissue 
more closely, making it valuable in evaluating therapeutic responses and predicting 
whether treatments will be clinically relevant. 
 
Using model organisms as discovery tools  
As mentioned previously, animal models have been useful in understanding 
disease progression and effects of different treatments. While these models are useful in 
understanding the progression of disease and the effects of specific therapeutic targets, 
these animal models are rarely used to identify disease-relevant (and potentially novel) 
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pathways in lung disease. In the few cases where they are, the processes to do so 
appear complex. Hence, the use of simpler model organisms is one way to bypass this 
complexity and perform genetic screens more easily and/or at a larger scale (Figure 
1.3). Studies with Drosophila melanogaster and Caenorhabditis elegans have procured 
pathways or recapitulated known pathways that are relevant to COPD (Green et al., 
2009; Prange et al., 2018). In Drosophila, RNA sequencing of trachea tissue from 
untreated and CS-exposed larvae revealed that gene expression was altered for 143  
genes (Prange et al., 2018). Interestingly, some of these genes function in Nrf2, TGF-β, 
and JAK/STAT signaling pathways. These pathways have already been identified as 
relevant to COPD disease progression, making Drosophila another option to study these 
pathways in terms of CS exposure (Prange et al., 2018). As for C. elegans, the impact of 
CS exposure on genes that regulate innate immunity was investigated through 
microarray analysis. One of the genes identified, lbp-7, encodes for a lipid binding 
protein (Green et al., 2009). Interestingly, mRNA levels for the human orthologue of lbp-
7, Fatty Acid Binding Protein 5 (FABP-5), were lower in COPD patient cells compared to 
cells from non-diseased smokers (Green et al., 2009).  
In lieu of using model organisms as discovery tools for COPD, I contributed to a 
project that involved using Dictyostelium discoideum, a social amoeba, to identify 
disease-relevant pathways in the first portion of my thesis (Kliment et al., 2021). In a 
genetic selection for suppressors against CS-induced insults, a variety of genes came 
out as protective against CS (Kliment et al., 2021). This list of suppressors included 
cytoskeletal, metabolic, protein folding, and translational proteins (Kliment et al., 2021). 
We were interested in further studying one of the proteins, adenine nucleotide 
translocase (ANT), because of its robust protection against CS in Dictyostelium. ANT is 
a mitochondrial protein in the inner membrane that is responsible for transporting 




appears to be a novel target for COPD outside of inflammation. Hence, we conducted 
further studies to understand how it is protective against CS and assess its relevance to 
disease onset and progression. We proceeded to study ANT in human disease models 
in the context of previously mentioned research areas that may underlie COPD (i.e., 
mitochondria and airway hydration). 
 
Figure 1.3. Various model organisms can be utilized to identify new and relevant 
biology in COPD. Mice have been heavily used to study COPD and understand 
disease progression, but the processes that come with identifying new essential 
disease biology are more complex in both human and mouse. Interestingly, there is 
emerging research on finding additional disease-relevant biology with simpler model 
organisms. New pathways affected by cigarette smoke have been identified in in vitro 
cell culture models, C. elegans (23), Drosophila (47), and social amoeba Dictyostelium 
discoideum (32). By utilizing these simpler models, there is the potential to recapitulate 
major findings or discover novel research on COPD, which can then be further studied 




As a follow-up to the first portion of my thesis work, the second portion focuses 
on ANT in the less obvious context of cell mechanics and cytoskeletal systems. Our lab 
previously established that defects in cytoskeletal systems in Dictyostelium are 
bypassed through the overexpression of ANT (Kliment et al., 2021). From our COPD 
studies, we discovered that ANT affects ATP production. This result suggests that 
cytoskeletal function affects ATP production in a more complex feedback system 
contrary to the traditional view of ATP flowing into cytoskeletal remodeling. Since CS 
also affected cells by altering cell structure and affects ATP production, it was of interest 
for us to observe whether ANT can alter cellular structure by increasing ATP production 
(Kliment et al., 2021; Nishida et al., 2017). Based on these findings, we can further 
elucidate how ANT is protective against CS, potentially through changes in cellular 
structure. 
 















Chapter 2: Materials and Methods 
Cell strains and culture 
Human cell culture 
 Human bronchial epithelial cells (HBE), immortalized by Cdk4 and hTERT, were 
a gift from John Minna (University of Texas Southwestern Medical Center, Dallas, 
Texas). HBE cells were generally grown in keratinocyte serum-free media 
(ThermoFisher). When these cells reached 70-80% confluent, they were split after being 
trypsinized with 0.05% trypsin and treated with trypsin neutralizing solution. 
 Primary normal human bronchial epithelial cells (NHBE) were obtained from 
Lonza and MatTek. Vials of cells were thawed and grown on flasks coated with Type I 
collagen (50 µg/ml in 0.02N acetic acid). After cells reached 80-90% confluency, they 
were split after trypsinization with 0.05% trypsin and neutralization with trypsin 
neutralizing solution. Cells were seeded on PET inserts coated with Type I collagen at a 
density of 90,000 cells per 12-well insert (0.4-µm pore, 1.12 cm2 area, Corning Costar) or 
30,000 cells per 24-well insert (0.4-µm pore, 0.33 cm2 area, Corning Costar) with both 
apical and basal media. Once a confluent monolayer was formed, apical media was 
removed, and cells were grown at air liquid interface (ALI) for three-six weeks until they 
differentiated into an airway epithelium.  
NHBE cells from Lonza and MatTek were initially grown in BEGM media (Lonza) 
with recommended supplements (bovine pituitary extract, insulin, hydrocortisone, 
epinephrine, transferrin, recombinant human epidermal growth factor, retinoic acid, 
triiodothyronine (T3), and gentamicin sulfate amphotericin-B) with additional bovine 
pituitary extract (12.6 µg/mL, AthenaES), bovine serum albumin (BSA) (final 
concentration of 1.5 µg/mL, Sigma-Aldrich), retinoic acid (final concentration of 0.1 µM) 
and epidermal growth factor (final concentration of 25 ng/mL). When NHBE cells were 
grown at ALI, BEGM media (Lonza) and DMEM media were combined with 
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recommended Lonza supplements (1 supplement pack per 500 mL of media) with 
additional bovine pituitary extract (12.6 µg/mL, Lonza and AthenaES), BSA (final 
concentration of 1.5 µg/mL, Sigma-Aldrich), and retinoic acid (final concentration of 0.1 
µM).  
 
Dictyostelium cell culture 
A list of transformed strains used is provided in Table 1. Vegetative D. 
discoideum cells were routinely grown in Hans’ Enriched HL-5 (1.5x HL-5 medium 
supplemented with ForMedium (FM, 8% final concentration), penicillin (60 U/mL), and 
streptomycin sulfate (60 mg/mL)). Cells were grown at 22°C on polystyrene Petri dishes 
and passaged by simple pipetting before cells reached the stationary phase (between 
2x106 and 6x106 cells/mL). Cells grown in suspension were placed in Erlenmeyer flasks 
at 180 rpm at 22°C. 
Table 1. List of transformed Dictyostelium strains used 
Background Strain Plasmids transformed 
KAx3 pDM181 




Mutant cell line generation 
Adenovirus gene expression in human bronchial epithelial cells 
 Adenovirus constructs were developed for gene delivery of control eGFP, ANT1-
GFP (Ad-h-SLC25A4/eGFP, GenBank BC008664.1), and ANT2-GFP (Ad-h-
SLC25A5/eGFP, GenBank BC056160.1) from Vector Biolabs (Malvern, PA) in NHBE 
and HBE cells. Cells were infected with an MOI of 40-80. Protein expression and 
localization were confirmed. Adenoviral infection efficiency was ∼85–95% with confirmed 
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expression of ANT-GFP isoforms. Adenoviral infected cells were used for experiments 
48 h after initial virus exposure. 
  
Dictyostelium mutant cell line generation 
The plasmids for the untagged, GFP-tagged, or mCherry-tagged fusions of 
myosin-II heavy chain (mhcA), cortexillin-I (ctxA), racE, and ancA have been described 
previously (Effler et al., 2006; Kee et al., 2012; Kliment et al., 2021; Lee et al., 2010; Ren 
et al., 2014). Dictyostelium cells were transform with 1 µg of expression plasmids using a 
Genepulser-II electroporator (Bio-Rad, Hercules, CA). Transformed cells were grown in 
enriched Hans’ HL-5 media for 24-48 hr at 22°C before being grown in Hans’ enriched 
HL-5 with G418 (typically 10-15 µg/mL but determined using kill curves and/or 
optimization of transformation efficiency with the empty plasmid). Media with drug was 
changed every 2-3 days until clones were harvested.  
 
In vitro cigarette smoke exposure 
 Cigarette smoke exposure comprised of either treatment with cigarette smoke 
extract (CSE) or gaseous CS through the Vitrocell system. CSE was made by bubbling 
one research grade cigarette (Type: 3R4F, Tobacco Health Research Institute, 
University of Kentucky, Lexington, KY) into 25 mL of media over 6 min with a peristaltic 
pump. This solution was considered 100% CSE, which was then filtered with a 0.22-µm 
filter. For gaseous CS exposure, NHBE grown on inserts at ALI were inserted into 
chambers in the Vitrocell system as demonstrated in Figure 2.1. Cells were exposed to 
air or two cigarettes smoked over 16 min using an International Organization for 






Mitochondrial reactive oxygen species production was assessed using MitoSOX 
Red (ThermoFisher) staining in HBE cells treated with adenovirus and CSE. Cells were 
washed once with PBS and incubated with MitoSOX for 10 min at 37°C, 5% CO2. Cells 
were washed three times with PBS and placed in L-15 Leibovitz medium for imaging 
using the High Content Imager. For cell analysis, fluorescence intensity of mitochondria 
was assessed with exclusion of the nucleus. For cell analysis, MetaXpress software 
(Molecular Devices) was used to separate cells infected with adenovirus constructs from 
uninfected cells. The average fluorescence intensities of MitoSOX staining in 
mitochondria were determined with exclusion of the nucleus. Approximately 300–400 
cells were analyzed per well for a total of 700–1500 cells per group. Across all 
replicates, 2800–4500 cells per group were evaluated. 
 
ATP measurements 
HBE intracellular ATP concentrations were measured after cells were seeded 
onto 6-well plates and infected with adenoviral ANT1, ANT2, and GFP control for 48 hr. 
 
Figure 2.1. Schematic of cigarette smoke exposure chamber of Vitrocell smoking 
machine. Transwell inserts are kept humidified and at 37°C through the flow of warmed 
water through the chamber. Smoke is delivered through the funnel positioned directly 




The cells were then treated with media alone or 20% CSE for 4 hr. Cell lysates were 
collected with lysis buffer and 300 µM of ecto-ATPase inhibitor ARL 67156 (Sigma), 
flash-frozen in liquid nitrogen, thawed on ice, and boiled for 5 min. The concentration of 
each sample was assessed via a luciferin-luciferase bioluminescence ATP 
Determination Kit (ThermoFisher). Luminescence was detected in a microplate reader 
(FLUOstar Omega, BMG Labtech) and integrated over 10 s. Concentrations were 
determined using a standard curve with a linear range between 0.5 and 1000 nM ATP. 
The ATP concentration in mM per HBE cell was calculated by considering the cellular 
volume of and the amount of ATP in a single HBE cell as demonstrated in the following 
equation: Amount of ATP per cell = (Concentration of ATP per cell) (Volume of cell). 
Spherical cell volume was determined after measuring the diameter of trypsinized HBE 
cells on an epifluorescence microscope (Olympus). The amount of ATP for one cell was 
derived from the amount of protein in one cell found via Bradford assay (BioRad).  
 For Dictyostelium cells, cytoskeletal mutants, their respective rescue lines, and 
ANT overexpressed cell-lines were prepared beforehand. Their intracellular ATP was 
measured via luciferin-luciferase as described above. Dictyostelium spherical cell 
volume was determined after measuring the diameter of settling cells after resuspension 
on an epifluorescence microscope.  
 
Seahorse XF mito stress assay 
The following protocol was adapted from (Lay et al., 2016). The Seahorse XF 
mito stress assay (X96 Flux Analyzer, Agilent) was used to assess metabolic activity for 
Dictyostelium cytoskeletal mutants. Cells were resuspended in SIH media (FM media 
with final concentrations of 20mM sodium pyruvate and 5mM malic acid, pH to 7.4) in 
96-well Seahorse assay plate coated with Matrigel (Agilent). Oxygen consumption rate 
(OCR) was measured through the Seahorse Flux Analyzer according to the 
28 
 
manufacturer’s protocol (Agilent). After 3 basal measurements, various drugs were 
injected into wells and mixed before subsequent OCR measurements. Oligomycin (20 
µM, ATP synthase inhibitor) was injected, followed by FCCP (10 µM, mitochondrial 
uncoupler), Rotenone (30 µM, ETC complex I inhibitor), and then Antimycin A (30 µM, 
ETC complex III inhibitor). The data output results in various metabolic outputs such as 
basal respiration, ATP production, maximal respiration, spare respiratory capacity, 
proton leak, and non-mitochondrial respiration. 
 
Ciliary function studies 
Airway surface liquid (ASL) height 
ASL height was measured by adding 10 kD-Texas Red-dextran (ThermoFisher, 
diluted in PBS) to NHBE or HBE cells grown at air liquid interface (17.5 µL per 12-well 
insert and 6.7 µL per 24-well insert). The apical surface was washed with PBS about 16 
hr prior to the addition of Texas Red-dextran. After 4 hr of incubation with Texas Red-
dextran, cells were imaged. Right before imaging, Fluorinert (100 µL per 12-well insert 
and 30 µL per 24-well insert, Sigma) was added to the apical surface to prevent 
evaporation. Inserts were imaged on a Zeiss 780 confocal microscope equipped with a 
heat and CO2 controlled stage and 40x water objective. ASL was imaged by acquiring 
3x3 or 4x4 tiled z-stacks, and each z-stack image was captured at a step size of 0.46 
µm. For experiments with ANT inhibitors, carboxyatractyloside (CATR, 20 μM, Sigma) 
and bongkrekic acid, (BKA, 4 μM, Sigma) in PBS were added to the Texas Red dextran 
dye and applied to the apical surface of ALI cultures 4 hr prior to ASL assessment. For 
apyrase treatment, 10 units of apyrase (Sigma) was added with Texas Red-dextran as 
described above 4 hr prior to ASL assessment.  
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Thickness across the sample was computed using a custom script, written in 
Matlab (Mathworks, Natick, MA). Briefly, for each value x in the three-dimensional 
images, Im(x, y, z), the resultant (y, z) slice was segmented using adaptive thresholding 
(Matlab command: imbinarize), followed by operations to fill holes (imfill), morphological 
opening (imopen) and filtering of small regions (bwareaopen). The threshold level was 
adjusted after preprocessing the complete image and the process repeated. For each y 
in this binary image, the number of segmented pixels was counted, giving a measure of 
the thickness in the (x, y) location; see Supplementary Information 1. This gave a 
histogram of depths over the image. An average depth was computed for all pixels in 
which a non-zero depth was detected (to avoid edge effects). The process was repeated 
by fixing y and working with the (x, z) slice. The differences between the averages were 
typically less than 1–2%. Thickness in pixels was converted to µm using a slice 
thickness of 0.46 µm, the step size used to collect the z-stack. 
 
Ciliary beat frequency 
NHBE cells were infected with adenovirus 48 hr before ciliary beat frequency was 
assessed. Inserts at ALI were placed in a 12-well Falcon plate and supplemented with L-
15 Leibovitz medium, and they were then imaged 2 min later. Videos were taken on a 
Leica spinning disk confocal with a 40x water objective. About 3-5 videos were taken for 
each insert from the top down at 160 frames/s over 4 s. Each insert was treated with 
either air or CS through the Vitrocell system before being imaged again. After this 
second imaging session, cells rested for 4 hr afterwards at 37°C and 5% CO2 before 
being imaged for a third time. 
 Ciliary beat frequency (CBF) was measured using a custom Matlab script. 
Individual images from a video consisting of N frames were used to create a three-
dimensional matrix Imk (x, y), where (x, y) denotes location in the image of each pixel, 
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and k ∈ 1, . . . , n is the frame number. For each (x, y), the corresponding sequence of 
intensities was first normalized: 
𝑝𝑖,𝑗(𝑘) =









so that 0 ≤ pi,j (k) ≤ 1 and filtered by removing the mean value:  







The Fast-Fourier transform (FFT) of p˜ i,j (k) was obtained using the MATLAB command 
fft:  




,   𝑛 = 0, … , 𝑁 − 1. 
and the corresponding single-sided power spectrum was computed (where N is even): 
?̃?𝑖,𝑗(𝑛) = {
|𝑞𝑖,𝑗(0)|, 𝑛 = 0
2|𝑞𝑖,𝑗(𝑛)|, 𝑛 = 1, . . . , 𝑁/2
 
This gives a power spectrum for each pixel. 
To determine the frequency of beating, we carried out two approaches. In the 
first, we found the frequency with highest power density for each of the pixels. We then 
used a threshold (set at 0.125 A.U.) to determine whether there was any detectable 
power in that pixel or not. The frequency with highest power was determined, and this 
data aggregated over all pixels meeting this threshold. The data between 2 and 20 Hz of 
the corresponding histogram was then normalized and fit by a single Gaussian, 
 𝛼exp−((𝑓−𝜇)/𝜎)
2
 where f is the frequency, using the command fit. The value of µ was 
used as a measure of beating frequency.  
In the second method, we aggregated the power spectra from all pixels (with no 
thresholding): ?̅?(𝑛) = ∑ ?̃?𝑖,𝑗(𝑛)𝑖,𝑗  and fit the data between 2 and 20 Hz to a Gaussian 
mixture model using three modes. This resultant µ value with the greatest contribution to 
31 
 
the mixture model was used. Both methods provided similar estimates, so the data we 
reported in our publication used Method 1 frequencies. 
 
Immunofluorescence imaging 
For paraffin-embedded human lung tissue, samples were adhered to slides for 
60 min at 60°C on a slide warmer and then deparaffinized with xylene and ethanol. 
Samples were then placed in sodium citrate at 95°C for 20 min for antigen retrieval. For 
HBE grown on slides or on inserts at ALI, cells were fixed in ice-cold 4% 
paraformaldehyde for 10 min. Prepared human lung tissue or cells was processed as 
described below. 
Samples were washed with 1x PBS three times and then blocked in 1X PBS + 
0.05% Triton X-100 + 0.5% BSA for 45 min at room temperature. This was followed with 
3 washes in 1X PBST (1X PBS + 0.05% Triton X-100). Primary antibody was incubated 
on sections in PBST overnight at 4°C. Samples were washed with PBST 5 times on the 
next day. They were then incubated with secondary antibody in PBST for 60 min at room 
temperature, away from light, and then washed with PBST 5 times. For inserts at ALI, 
the transmembrane was cut out and placed on glass slides.  Sections were mounted in 
Prolong Diamond Antifade Mounting Agent (Molecular Probes, ThermoFisher) and 
allowed to cure for at least 24 hr at room temperature in the dark. Images were routinely 
taken on Zeiss confocal microscopes at 40x or 63x with excitation lasers at 488 for GFP, 
561 for mCherry, and 633 for far-red fluorescent proteins. Sections were stained with the 
following primary antibodies: ANT1 (Abcam #ab102032 rabbit polyclonal, 1:100), pan 
ANT (anti-ANT1/2/3 Abcam, #ab110322, mouse monoclonal 1:100), ANT2 (5H7, from S. 
Claypool (Jones et al., 1992), 1:100), ANT2 (Abcam, #ab118076, mouse monoclonal, 
1:100), ANT2 (Abcam, #ab222843, 1:100), ANT2/3 (Abcam, #ab230545, 1:100), and 
goat anti-mouse, anti-rabbit or anti-chicken Alexa 488, 555 and 647 (Molecular Probes). 
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Dictyostelium cell viability 
Cells were seeded in 10 mL of Hans’ Enriched HL-5 medium in 150 mL 
Erlenmeyer flasks at a starting concentration of 1x105 cells/mL. They were shaken in 
22°C incubator at 180 rpm, and the cell concentration was measured and recorded 
roughly every 24 hr using a hemocytometer. When cells reached the later point of 
exponential growth phase (about 5-6x106 cells/mL), cultures were split down to a 
concentration of 0.5 - 1 x 105 cells/mL. Cell density continued to be measured roughly 
every 24 hr. Data was normally acquired from second and third cycles of suspension 
culture. Relative growth rates were determined by plotting cell densities versus time. The 
resulting exponential phase curves were fitted to single exponential equations using 
KaleidaGraph (Synergy Software). Growth rate (k) was determined for each growth 
curve through the exponential growth equation:  
𝑛(𝑡) = 𝑛0𝑒
𝑘𝑡 
where n(t) = population at time t, n0 = initial population concentration, and k = relative 
growth rate. 
 
Western analysis  
 Western analysis was done with lysates from Dictyostelium, human airway 
epithelial cells, and yeast S. cerevisiae. Protein concentration was determined by 
Bradford Assay (Pierce). Human airway lysates were obtained using RIPA buffer with 
protease inhibitor cocktails I, II, and III (Sigma), RNase, and 150 nM aprotinin. 
Dictyostelium lysates were obtained after flash freezing samples in liquid nitrogen. Yeast 
protein lysates were obtained from yeast expressing human ANT1-4 (Δaac[EV], 
Δaac[ANT1], Δaac[ANT2], Δaac[ANT3], Δaac[ANT4], OD600=3 per group) via alkaline 
lysis with NaOH/β-mercaptoethanol and trichloroacetic acid. Samples were run on 10-
15% acrylamide gels and transferred onto nitrocellulose membranes. Blots were 
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incubated with primary antibodies overnight at 4°C and then imaged on the Li-Cor 
Odyssey CLx Blot Imager using Li-Cor fluorescent secondary antibodies. The following 
primary antibodies were used: human ANT1 (1:500, ab1F3H11 from Steven Claypool, 
mouse), ANT2 (1:500, ab5H7 from Steven Claypool (Jones et al., 1992), mouse), ANT2 
(1:500, ab5695 from Steven Claypool, rabbit), ANT1 (1:500, Abcam, #102032, rabbit), 
pan ANT (1:500, anti-ANT1/2/3 Abcam, #ab110322, mouse), ANT2 (1:500, Abcam, 
#ab118076, mouse), ANT2 (1:500 Abcam, #ab222843, rabbit), and ANT2/3 (1:500, 
Abcam, #ab230545, rabbit). 
 
Statistics 
Normally distributed data was analyzed with an ANOVA followed by a Fisher’s 
LSD post-test. Kruskal-Wallis and Mann-Whitney were used for nonparametric data sets. 
Statistical analysis was performed and graphed using KaleidaGraph (Synergy Software) 
or Graphpad Prism. 
 













Chapter 3: Adenine Nucleotide Translocase as a Protector Against Cigarette 
Smoke Through Regulation of Metabolism, Airway Hydration, and Ciliary Function 
 As previously mentioned, our lab previously identified adenine nucleotide 
translocase (ANT) as protective against cigarette smoke (CS) by utilizing Dictyostelium 
discoideum as a discovery tool. Using Dictyostelium, we created ~35,000 transformants 
with a cDNA library and grew them in a cigarette smoke extract (CSE) made from media 
bubbled with CS, one of the main causes of COPD. We selected for transformants that 
were protected from CS-induced growth defects and isolated their genes. ANT was a 
gene that offered complete protection of cell viability against CS (Kliment et al., 2021). 
When studies were transferred into immortalized human bronchial epithelial cells (HBE), 
we found that ANT also protected against CS by increasing cell viability. With this 
information, we were interested in understanding the protective mechanisms of ANT 
against CS. By understanding the core cellular processes of ANT in human or mouse 
models, we hope to harness their protective properties to treat COPD (i.e. screen for 
pharmacological agents that will promote target activation and induce protective 
phenotypes). Overall, this project was a large collaborative effort between many talented 
scientists. Below, I specifically describe my contributions to this study. 
 
ANT regulates metabolic activity by affecting oxidative stress 
 As a transporter of ATP/ADP in the mitochondria, we were interested in 
examining whether ANT regulated mitochondrial activity in the context of CS. 
Mitochondrial function, as mentioned before, is disrupted after CS exposure. Morphology 
and metabolism are affected negatively, and mitochondria are also a source of 
endogenous reactive oxygen species (ROS) when under stress. ROS is considered a 
significant drive in COPD onset, and interestingly, there is evidence that ANT can 
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change levels of ROS (Kretova et al., 2014). Thus, we proceeded to examine whether 
ANT could protect against CS-induced ROS.  
 MitoSOX Red was used as a marker for ROS in HBE cells. Cells were exposed 
to either 0% or 20% CSE for 1, 4, or 24 hours and imaged on a high content imager 
(Figure 3.1). We observed that CSE exposure did not significantly affect the levels of 
MitoSOX. Nonetheless, after 1 hour, ANT1 overexpression decreased MitoSOX 
expression slightly. Both ANT1 and ANT2 overexpression increase MitoSOX expression 
after 4 and 24 hours of CSE exposure. Something to note is that each experimental 
group was heavily sampled through the high content imager, which results in slight 
changes producing a statistically significant difference. Whether these slight changes are 
biologically relevant is unknown, but the increase in MitoSOX from ANT1 and ANT2 
overexpression may coincide with an increase in electron transport chain flux. This 
increase in flux is reflected by an increase in cellular respiration, which had been 
demonstrated in our other metabolic experiments (Kliment et al., 2021).  
 
Intracellular ATP levels of HBE after CS treatment 
 Other aspects of mitochondrial function in the context of CS that we examined 
were metabolic activity and ATP production. We demonstrated that ANT overexpression 
increased ATP production in HBE after exposure to CS via changes in oxygen 
consumption rate (Kliment et al., 2021). Hence, we proceeded to validate whether this 
change in ATP production would reflect in changes in the amount of intracellular ATP. 
Intracellular ATP concentrations can be indicators of cell viability and energetic state, 
and there is evidence that CS can affect the concentration of ATP (van der Toorn et al., 
2007). We measured the amount of steady-state ATP in HBE cells using a luciferin-
luciferase assay and found the concentration to be around 8 mM of ATP per cell. ATP 
concentrations were also measured after exposure to 20% CSE, and interestingly we did 
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not see a difference from control cells and in cells overexpressing ANT1 or ANT2 
(Figure 3.2). This result could indicate that while steady-state concentrations of ATP do 
not change in the cell, ATP flux could still increase or decrease, and this coincides with 
the cell using more or less energy overall. 
 
ANT enhances airway hydration and ciliary function 
As stated previously, the airway epithelium acts as a barrier to toxins and 
particulates and removes them from the airway. Airway hydration and normal ciliary 
function are important components to the epithelium’s barrier function and are both 
negatively affected by CS exposure. In addition, ATP plays an important role in 
maintaining normal ciliary function via providing energy for ciliary beating (Lazarowski et 
al., 2004). Extracellular ATP is also responsible for signaling pathways that activate the 
 
Figure 3.1. ANT modulates mitochondrial reactive oxygen species. Boxplot 
showing mitochondrial superoxide production (MitoSox) in HBE after CSE with ANT 
overexpression. Horizontal dotted line represents the median for the 1 hr control group. 
Boxplots show the median with the box delineating the 1st and 3rd quartiles. The 
whiskers represent 1.5*IQR (interquartile range). Statistics performed by Kruskal-
Wallis and two-tailed Mann-Whitney U tests. P-values represent differences from 




cystic fibrosis transmembrane conductance regulator (CFTR) and block the epithelial 
sodium channel (eNaC). This blockage of eNaC and activation of CFTR results in airway 
hydration by the release of chloride ions and water (Huang et al., 2001). The importance 
of ATP in ciliary beating and airway hydration propelled us to examine whether ANT 
could regulate them. 
 
We proceeded to assess airway hydration and ciliary beating with ANT 
overexpressed in normal bronchial epithelial cells (NHBE) grown at air liquid interface 
(ALI). These cells differentiated into an airway epithelium, and we confirmed that they 
produced beating cilia. We also confirmed both ANT1 and ANT2 expression in these 
cells after adenoviral infection. To assess airway hydration, the height of the airway 
surface liquid (ASL, the liquid layer atop the airway epithelium) was measured via 
confocal microscopy. Interestingly, ANT2 overexpression increased ASL height about 
2.3-fold above GFP-control cells and ANT1-overexpressed cells (Figure 3.3A). To verify 
 
Figure 3.2. Total intracellular ATP does not change after cigarette smoke 
treatment or with ANT overexpression. Measurements of total intracellular ATP in 
HBE with ANT1 or ANT2 overexpression ±20% CSE, yielding a total intracellular [ATP] 





that ANT activity increased ASL height, we also measured ASL height after treating cells 
with inhibitors of ANT, carboxyatractyloside (CATR) and bongkrekic acid (BKA). Both 
inhibitors abrogated the increase in ASL height by ANT2 overexpression (Figure 3.3A). 
In addition, we also used apyrase, an ATP hydrolyzer, and it prevented the increase in 
ASL height by ANT overexpression as well (Figure 3.3A). This result confirmed that the 
presence of extracellular ATP was required for an increase in ASL height. Overall, ANT2 
overexpression increased ASL height via extracellular ATP, suggesting that it regulated 
airway hydration. We found that ANT2 can actually regulate airway hydration regardless 
of whether cells had cilia. HBE cells, which do not grow cilia, were grown at ALI and ASL 
was measured. ANT2 overexpression in HBE caused an upward trend in ASL height, 
and this increase in height was also inhibited by CATR and BKA (Figure 3.3B). 
To assess ciliary beating, videos were taken of NHBE treated with air or gaseous 
CS and ciliary beat frequency (CBF) was measured. There was no significant difference 
in CBF between air-treated control and ANT2 overexpressed cells (Figure 3.4). CS did 
slow down CBF for control cells, but ANT2 overexpression notably did not alter CBF 
(Figure 3.4). Even after a rest period, CBF continued to persist at baseline in CS-treated 
cells overexpressing ANT2 while CBF for control did not return to baseline (Figure 3.4).  
    
ANT localizes to the plasma membrane of differentiated NHBE 
 As stated before, the release of extracellular ATP contributes to airway hydration 
(Schwiebert and Zsembery, 2003). A few transporters have been implicated in shuttling 
ATP outside of the cell, but the list is not yet exhaustive (Schwiebert and Zsembery, 
2003). Because CATR, a membrane-impermeable inhibitor, blocked the increase in ASL 
height caused by ANT2, we hypothesized that ANT2 may be localizing to the cell 





We analyzed ANT localization in both human lung tissue and NHBE cells grown 
at ALI (Kliment et al., 2021). For the NHBE cells, vertical sections of the inserts were cut 
 
Figure 3.3. Airway surface liquid height increases with ANT2 overexpression. A) 
X-Z plane confocal images of ASL labeled with Texas Red- dextran were collected and 
used to measure ASL thickness. Images were also taken of NHBEs treated with ANT 
inhibitors, carboxyatractyloside (catr, 20 µM) and bongkrekic acid (bka, 4 µM), and an 
ATP hydrolyzer, apyrase (apy). n=5-11 inserts with P-values as presented. B) ASL was 
also measured for HBE cells, which do not have cilia. Representative orthogonal views 
of ASL height from HBE cells and ASL quantification are presented. n=5-7 inserts with 




and processed for immunofluorescence imaging (IF). Through IF, ANT was visibly near 
the cell surface and along the cilia (Figure 3.5A). ANT signal at the cell surface and/or 
cilia was quantified and compared to IgG control to confirm that the signal was above 
background (Figure 3.5B,C,D). To confirm that the IF signal was indeed ANT, multiple 
antibodies were used to probe for ANT. These antibodies were confirmed to bind to ANT 
through western analysis of lysates from yeast expressing human ANT1-4 (Figure 3.6).   
The experiments done with human lung tissue offered similar results (Kliment et 
al., 2021). We also confirmed that ANT co-localizes with mitochondrial markers and 
ciliary markers and that there was no evidence of fluorescence bleed-through from those 
markers (Kliment et al., 2021). Overall, our localization studies point to ANT being at the 
cell surface near the cilia, making it poised to be an extracellular ATP transporter. 
 
 
Figure 3.4. Ciliary beat frequency is not altered with ANT2 overexpression after 
cigarette smoke exposure. Videos were taken of cilia beating on NHBEs before, 30 
mins after, and 4 hours after treatment with air or CS. ANT2 overexpression maintains 
normal CBF after CS treatment while CBF for control and ANT1 cells decreases and 
remains lower than baseline CBF as demonstrated in the heatmaps and CBF 
quantifications. CBF stayed at a normal level with ANT2 overexpression even after a 






Figure 3.5. ANT localizes at the cell surface and cilia in human bronchial 
epithelial cells. A) Frozen vertical sections of normal human bronchial epithelial cells 
grown at air liquid interface were stained with a panel of ANT antibodies (red). 
Brightfield images are provided to show cilia on the apical surface of the airway 
epithelium. B) For quantification of ANT signal, regions of interest (ROIs) were traced 
in the cilia, the mitochondrial layer directly below the apical surface, and in the 
background. C-D) ANT signal in the ROIs were background subtracted and normalized 
to IgG secondary-only controls, demonstrating significant increases in both the cilia 
and mitochondrial layer. n=cells from 3-5 patients. Results of an ANOVA test with 












Figure 3.6. Western analysis of ANT antibody specificity. Antibody specificity was 
determined for rabbit and mouse anti-ANT antibodies utilizing yeast strains with 
expression of the individual human ANT paralogs, ANT1-4. Hexokinase-2 was used as 




Chapter 4: Discovering and deciphering the feedback between metabolism and 
cytoskeletal function 
 Cell shape change is involved in several processes including cytokinesis, tissue 
development, wound healing, and immune function. These processes are further 
implicated in diseases such as pancreatic cancer progression and as mentioned 
previously, COPD. Maintaining normal airway structural integrity is vital to prevent COPD 
onset (Aghapour et al., 2018). Our group has found that continual CS affects actin 
assembly and cell mechanics in NHBE cells (Nishida et al., 2017). This study along with 
others highlight that cell structure and cytoskeletal function should be topics of interest 
for COPD therapeutic development. 
 In the context of ANT, we have several pieces of evidence that point to ANT 
having interactions with cytoskeletal modulators in Dictyostelium (Figure 4.1). ANT 
overexpression acted as a genetic suppressor of two mutants, a null mutant of racE 
small GTPase and an engineered wild-type strain with integrated assembly-incompetent 
myosin II phosphomimetic 3xAsp (Ren et al., 2014). Both mutants have defects in cell 
mechanics and cytokinesis fidelity. Because ANT is known to alter the energetic state of 
the cell, these results provoke the idea that understanding the metabolic state of the cell 
can give further insight into overall cell mechanics, motility, and processes like epithelial-
to-mesenchymal transition (EMT). Indeed, others are beginning to find such connections 
between metabolism and cytoskeletal function (DeWane et al., 2021). By continuing to 
learn about these connections, we can begin to apply this knowledge to diseases like 
COPD. We can elucidate more protective phenotypes that ANT may have in the context 
of cell structure. 
 Here, Dictyostelium was used to understand the feedback between metabolism 
and cytoskeletal function. With its genetic tractability, rapid growth rate, ease of 
handling, and genetic homology to mammalian cells, Dictyostelium is a suitable model 
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for studying cellular functions at a fundamental level. Genes responsible for cytokinesis, 
a significant cell shape change process, have been identified in Dictyostelium such as 
myosin II (myosin II; myosin II heavy chain is encoded by mhcA), cortexillin I (cortI; 
encoded by ctxA), and racE (racE) (De Lozanne and Spudich, 1987; Faix et al., 1996; 
Larochelle et al., 1996; 1997; Manstein et al., 1989). In addition, Dictyostelium has been 
used to study metabolism and as a model for mitochondrial diseases (Pearce et al., 
2019). Thus, Dictyostelium is an appropriate model to study both cellular mechanics and 
metabolism. In this study, we optimized assays for Dictyostelium and began surveying 
the relationship of ANT to these cytokinesis/cell mechanic proteins.  
 
Optimization of the Seahorse mito stress assay for Dictyostelium 
 The Seahorse Flux Analyzer has been widely used to measure metabolic activity 
in a variety of cell types. Oxygen consumption rate is measured after the injection of 
 
Fig. 4.1. Current understanding between ATP Production, Adenine 
Nucleotide Translocase (AncA/ANT), and cell shape control and mechanics. 
ANT overexpression suppresses racE nulls (unpublished) and WT(3xAsp myoII) 
(Ren et al., 2014).  In human airway cells, CS also inhibits cell mechanics (Nishida 
et al., 2017). Our previous studies also linked 14-3-3 to myosin II and racE to 
control contractility (Zhou et al., 2010). ANT suppresses CS by elevating ATP 
production and increasing ATP flux (Kliment et al., 2021). Further, racE nulls have 
reduced basal metabolic activity, which produces ATP. 
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various inhibitors of the electron transport chain, resulting in different metabolic outputs 
as demonstrated in Figure 4.2A. It has been adapted previously for use with 
Dictyostelium in a 24-well format (Lay et al., 2016). We proceeded to adapt this assay 
for a 96-well format. Because the responses from Antimycin A and Rotenone were not 
as effective initially, various concentrations of these drugs were used, and their 
effectiveness was monitored (Figure 4.2B,C). The final concentrations ultimately used in 
subsequent assays are as follows: oligomycin (20 µM), FCCP (10 µM), Antimycin A (30 
µM), and Rotenone (30 µM). 
 
 
Figure 4.2. Optimization of the Seahorse mito stress test for Dictyostelium in a 
96-well format. A) The Seahorse Flux Analyzer mito stress test is used to measure 
metabolic activity through changes in oxygen consumption rate (OCR) after the injection 
of various inhibitors of the electron transport chain. A range of concentrations for B) 
rotenone and C) antimycin A were tested separately in wild-type cells to determine the 





Changes in Cortexillin I expression modulates metabolic activity 
 With the optimized Seahorse assay, we began monitoring the metabolic activity 
of cytoskeletal mutants. We began with cortI null mutants, and interestingly we observed 
they had lowered metabolic activity compared to the wild-type strain (Figure 4.3A). The 
cortI null cell line was complemented with mCherry-tagged CortI and this interestingly 
increased metabolic activity to a higher level than WT (Figure 4.3A). Basal respiration, 
ATP production, and spare respiratory capacity were decreased in the cortI null cells 
(Figure 4.3B,C,D). Interestingly, when we monitor mitochondrial structures, we did not 
visually see a difference in mitochondrial distribution between cortI null and the rescue 
cell line. These data so far suggest that CortI is having an influence on metabolic 
























Figure 4.3. Dictyostelium cortexillin I null cells have reduced metabolic activity. 
A) The Seahorse Flux Analyzer mito stress test was used to measure differences in 
oxygen consumption rate (OCR) of wild-type (WT), cortI null, and mCherry-CortI 
complemented cortI null Dictyostelium cells. The mutants have reduced metabolic 
activity compared to WT and complementing with mCherry-CortI rescues metabolic 
function. These metabolic differences are reflected through B) basal respiration, C) 
ATP production, and D) spare respiratory capacity. n=30-32 wells. Results of Wilcoxon-




Chapter 5: Conclusions 
 From these studies, we have utilized Dictyostelium discoideum as a discovery 
tool to identify adenine nucleotide translocase (ANT) as protective against cigarette 
smoke (CS). Evidence suggests that mitochondrial dysfunction is a parameter that 
arises from CS exposure (Aghapour et al., 2020). Interestingly, we observed through the 
Seahorse assay that ANT protected metabolic activity in the presence of CS (Kliment et 
al., 2021). Yet, there was actually an increase in reactive oxygen species (ROS) via 
MitoSOX after ANT overexpression (Kliment et al., 2021). These results oppose other 
studies that have suggested that overexpression of ANT protects against oxidative 
stress in other cell types (Graham et al., 1997). Nonetheless, something to note is that 
MitoSOX measures mitochondrial superoxide. Mitochondrial superoxide is generated by 
an increase in mitochondrial membrane permeabilization and the respiration process, 
which are facilitated by ANT (Marchi et al., 2012; Vieira et al., 2000). Thus, the increase 
in MitoSOX correlates to an increase in ANT overexpression, but this may not be 
enough to correspond to an increase in cell death as we discovered in our apoptosis 
experiments (Kliment et al., 2021). 
 In addition to metabolism, we interestedly observed that ANT offered protection 
against CS by modulating mucociliary clearance in the airway epithelium. The airway 
epithelium is the first line of defense in the lung and acts a barrier to outside toxins. 
Along the surface of the airway is the airway surface liquid (ASL), an aqueous layer of 
water and mucus that traps these toxins (Lazarowski et al., 2004). Normal mucociliary 
transport consists of beating cilia which move the ASL along the airway to carry out 
trapped pathogens and particulates. CS can disrupt mucociliary transport by decreasing 
ASL height and ciliary beat frequency (CBF), leading to a build-up of mucus and 
pathogens that can cause inflammation and lead to COPD phenotypes (Tuder and 
49 
 
Petrache, 2012). Here, we observed that increased expression of ANT increased ASL 
height, and CBF did not slow down after treatment with CS.  
Considering that ANT is canonically a mitochondrial protein, it is interesting that 
we see it modulate processes such as airway hydration and ciliary function. An important 
component in mucociliary transport is the signaling pathways initiated by the release of 
extracellular ATP. A few transporters have been implicated in releasing ATP 
extracellularly including pannexin-1 (Seminario-Vidal et al., 2011). While ANT could 
modulate purinergic receptor signaling by increasing ATP production and flux, as we 
previously found, our data also suggest that ANT could also function as an extracellular 
ATP transporter. When measuring ASL height, we used two potent inhibitors of ANT, 
bongkrekic acid (BKA) and carboxyatractyloside (CATR). Both inhibitors prevented the 
increase in ASL height by ANT overexpression. CATR is a membrane-impermeable 
inhibitor, suggesting that it acts on ANT that is localizing to the cell surface (Vignais et 
al., 1973). Our metabolic data also verified that CATR does not work through 
intracellular ANT, so we proceeded to examine ANT localization in both human lung 
tissue and differentiated NHBE (Kliment et al., 2021). In both lung tissue and cells, we 
did observe ANT at the plasma and ciliary membranes through immunofluorescence 
imaging. We verified that the antibodies used were specific to ANT, which further 
supported our observations. Interestingly, other studies in hepatocytes and endothelial 
cells have also identified ectopic ANT, and both ANT1 and ANT2 have predicted 
secretion-signal sequences that could be the basic of their presence at the plasma 
membrane (Cardouat et al., 2017; Martinez et al., 2015). 
Another interesting avenue of protection that ANT may have is through cell 
shape change. Airway structure and essential in maintaining normal airway function. 
Modulators of actin, for instance, are thought to drive epithelial-to-mesenchymal 
transition (EMT) and airway tissue remodeling (Aghapour et al., 2018; Jiang et al., 
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2017). We have previously found that continual exposure to CS increases actin 
assembly and barrier permeability (Nishida et al., 2017). The idea that metabolism and 
the cytoskeleton interact with each other in a complex feedback system is growing, 
including through our own studies (DeWane et al., 2021). With the data we have thus far 
in Dictyostelium, we do see some evidence of decreased metabolic activity in cells 
lacking cytoskeletal proteins. Interestingly, cortI null mutants regained metabolic activity 
after being complemented with Cortexillin I. One hypothesis is that cortI mutants might 
have a less organized cortical actin meshwork, leading to an overall lower energetic 
state. Future work will be done with ANT overexpression to see if it might alleviate this 
issue for cortI null cells and lead to a partial rescue.  
 Overall, a tremendous need exists for discovering new core biology and ways to 
incorporate this into therapeutic development and in a more precision-based approach 
toward treating patients. The idea of using model organisms to discover new lung 
biology and studying new biology in human-disease models is especially promising, 
considering that the current models are concepts that have not changed for about three 
decades. From this idea, we identified ANT as a modulator of metabolism, ciliary 
function, airway hydration, and potentially cell shape change in the context of COPD. As 
mentioned previously, all these parameters are altered in COPD, making ANT a 
potential therapeutic target. Our discovery of ANT and its protective mechanisms are 
likely to provide the opportunities for new breakthroughs for COPD and other diseases 








Chapter 6: Future Directions 
 In the future, there are many directions the COPD and ANT project could take.  
Our data suggests that ANT is localizing at the cell surface, and we hypothesize that it is 
contributing to airway hydration by releasing extracellular ATP. To confirm this 
functionality at the cell membrane, we can measure extracellular ATP with luciferin and 
luciferase on top of ciliated NHBEs as other groups have done (Seminario-Vidal et al., 
2009). ATP concentrations can be measured at steady state at a single time point. ATP 
release rate can also be measured over time after treatment with a hypotonic solution, 
which will induce the release of ATP.  
We demonstrated that ANT is protective against CS in several ways, making it a 
potential therapeutic target for COPD. It would be interesting to begin developing a drug 
screen to probe for therapeutic molecules that can activate ANT or even phenocopy it.  
To screen for therapeutic molecules that will enhance ANT activity, a new drug library 
from the ChemCore of the Johns Hopkins Pharmacology and Molecular Sciences 
department could be used in a phenotypic screen with Dictyostelium. Dictyostelium will 
be used because our lab has experience using it to screen for compounds, and the initial 
genetic selection showed that Dictyostelium exposed to CS have hindered cell growth, 
an easily measurable phenotypic readout (Kliment et al., 2021). Hence, the screen will 
be based on cell death after exposure to CS. With 96-well plates, wild-type cells will be 
exposed to 40% CSE, as our preliminary data indicates that ANT is protective at this 
concentration. Cell survival will be visualized with a nuclear marker. For controls, wells 
with no cells, wild-type cells, and cells overexpressing AncA (the Dicty ortholog of ANT) 
will be subjected to this assay without drug treatment. The assay will be validated before 
it will be used with compounds. Compounds of interest from the screen will then be 
furthered tested with the concept of quantitative phenotypic fingerprinting, which is the 
identification of compounds based on their ability to induce quantifiable phenotypes that 
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modulate disease-relevant biology in cells. Essentially, we will observe whether the 
compounds can induce phenotypes in NHBEs which are characteristic of ANT OE (e.g. 
increase in ASL height, maintaining normal CBF). Compounds that phenocopy ANT OE 
may be relevant to treating disease because they can reverse CS injury. While the 
targets of these compounds of interest will be initially unknown, if they induce the same, 
or similar, quantitative phenotypes across the spectrum of readouts used to identify and 
characterize ANT OE, this increases the chances that ANT activity is involved. To begin 
validating whether ANT is a target for our hits, we will use a variety of techniques (e.g. 
western blotting) to see if there are changes in ANT expression after drug treatment. We 
will also utilize a thermal shift assay in a cellular format, called the cellular thermal shift 
assay (CETSA), to detect interactions (Jafari et al., 2014). This assay consists of treating 
cells with drug, collecting cell lysates in tubes, denaturing proteins with heat, and 
separating precipitated proteins in the pellet fraction from the soluble protein fraction. 
Both fractions are run on a western and then probed for a target of interest. Proteins that 
are bound to a drug, potentially ANT in this case, will remain soluble, while those that 
are not will be in the pellet. Even if ANT is not a target, compounds that phenocopy ANT 
can still have therapeutic potential since they will elicit protective properties and will not 
be toxic to human cells. This phenotypic cell process-based screen varies from the 
traditional target-based drug discovery screen, and we propose the compounds from a 
cell process-based screen have higher chances of being disease-relevant as a result 
(Figure 6.1). 
 In terms of the feedback between metabolism and cytoskeletal function, we will 
continue deciphering the relationship between ANT to the Dictyostelium cytoskeletal 
mutants. This includes performing the Seahorse assay with racE null cells, myoII null 
cells, cortI null cells, and these mutants with overexpressed ANT. ANT levels will also be 




expression. There is evidence that mitochondrial function and dynamics are integrated 
with cytoskeletal function (DeWane et al., 2021). Thus, we will also observe whether 
mitochondrial mass and subcellular distribution are altered in these mutants. 
Mitochondrial dysfunction can also be probed. MitoSOX will be used to observe if there 
is mitochondrial dysfunction through an increase in reactive oxygen species. The effects 
of ANT knockdown/inhibition will also be assessed. The impact of ANT depletion on 
cytokinesis fidelity and cell mechanics will be deciphered through western analysis, 
micropipette aspiration, compression, and cytokinesis dynamics.  
 
Figure 6.1. Cellular process-based drug discovery versus tradition target-
based drug discovery. As opposed to target-based discovery, cellular process-
based drug discovery is more focused on identifying quantitative protective 















 Both the Seahorse assay and mitochondrial assays are useful for gathering 
information on oxidative phosphorylation. Recently, others have found a connection 
between the metabolic state and the mechanical state of cells through glycolytic 
processes. It would be of interest to also consider the impact of glycolysis in our studies.  
Proteins such as activated AMPK (P-AMPK) and phosphofructose kinase-1 (PFK) are 
known to be altered in response to mechanical stresses and changes in metabolic 
activity (DeWane et al., 2021). We could examine the P-AMPK/AMPK ratios and PFK 
distribution in the cytokinesis mutants. Interestingly, changes in these proteins and 
glycolysis may be linked back to ANT. Proteins such as AMPK respond to changes in 
ATP levels, which is contributed by ANT activity. Overall, these experiments will aid in 
uncovering the impact of ANT on cellular mechanics, which can have future implications 
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